Literature DB >> 10880728

Plasma level monitoring of oxcarbazepine in epileptic patients.

D F González-Esquivel1, M Ortega-Gavilán, G Alcántara-López, H Jung-Cook.   

Abstract

BACKGROUND: Despite the wide use of oxcarbazepine (OXC) there is little data concerning the usefulness of plasma level monitoring with this drug in Mexican patients with epilepsy. The purpose of the present study was to determine whether OXC levels correlate with dose, age, weight, or drugs used concomitantly.
METHODS: Plasma levels of the antiepileptic drug OXC were evaluated in 214 patients with epilepsy. In each patient, plasma MHD (10-hydroxycarbazepine, the main metabolite of OXC) concentration was determined. Additionally, plasma protein binding was determined in 30 patients and affinity to red blood cells (RBCs) was evaluated in 50 patients.
RESULTS: Our results showed that the mean plasma level of MHD was 15.34 microg/mL, mean protein binding ranged between 30-40%, and the mean RBC concentration was 18.38 microg/mL. A relationship between dose/weight and plasma concentration was found (r = 0.5149, p <0.001). In addition, a linear relationship between plasma and RBC concentration was established (r = 0.8806, p <0.0001).
CONCLUSIONS: These results suggest that for OXC, routine RBC concentrations are not necessary to make drug adjustments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880728     DOI: 10.1016/s0188-4409(00)00056-4

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

1.  Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine.

Authors:  Anna Maria Mauro; Chiara Bomprezzi; Simonetta Morresi; Leandro Provinciali; Francesco Formica; Maurizio Iacoangeli; Massimo Scerrati
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

2.  Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.

Authors:  Yao Lu; Youxin Fang; Xunyi Wu; Chunlai Ma; Yue Wang; Lan Xu
Journal:  Eur J Clin Pharmacol       Date:  2016-11-29       Impact factor: 2.953

3.  Prospective study on long-term treatment with oxcarbazepine in pediatric epilepsy.

Authors:  Emilio Franzoni; Valentina Gentile; Alessandro Pellicciari; Caterina Garone; Luisa Iero; Stefano Gualandi; Duccio Maria Cordelli; Ilaria Cecconi; Filomena Caterina Moscano; Valentina Marchiani; Alessandra Errani
Journal:  J Neurol       Date:  2009-07-14       Impact factor: 4.849

Review 4.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.

Authors:  Penny Bring; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.